Eric Hsu
2022
In 2022, Eric Hsu earned a total compensation of $282.9K as Senior Vice President, PreClinical R&D at InMed Pharmaceuticals, a 29% decrease compared to previous year.
Compensation breakdown
| Option Awards | $29,456 |
|---|---|
| Salary | $253,461 |
| Total | $282,917 |
Hsu received $253.5K in salary, accounting for 90% of the total pay in 2022.
Hsu also received $29.5K in option awards.
Rankings
In 2022, Eric Hsu's compensation ranked 5,098th out of 5,669 executives tracked by ExecPay. In other words, Hsu earned more than 10.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,098 out of 5,669 | 10th |
Division Manufacturing | 2,800 out of 3,081 | 9th |
Major group Chemicals And Allied Products | 1,302 out of 1,396 | 7th |
Industry group Drugs | 1,223 out of 1,297 | 6th |
Industry Pharmaceutical Preparations | 886 out of 940 | 6th |
Source: SEC filing on October 28, 2022.
Hsu's colleagues
We found four more compensation records of executives who worked with Eric Hsu at InMed Pharmaceuticals in 2022.
2022
Eric Adams
InMed Pharmaceuticals
Chief Executive Officer
2022
Michael Woudenberg
InMed Pharmaceuticals
Chief Operating Officer
2022
Bruce Colwill
InMed Pharmaceuticals
Chief Financial Officer
2022
Alexandra Mancini
InMed Pharmaceuticals
Senior Vice President, Clinical & Regulatory Affairs
News
InMed Pharmaceuticals CEO Eric Adams' 2024 pay rises 13% to $415K
October 28, 2024
InMed Pharmaceuticals CEO Eric Adams' 2023 pay falls 22% to $368K
October 27, 2023
InMed Pharmaceuticals CEO Eric Adams' 2022 pay falls 36% to $468K
October 28, 2022
InMed Pharmaceuticals CEO Eric Adams' 2021 pay jumps 73% to $735K
October 28, 2021